Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Categories: ribocure clinic
-
-
Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel
Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel
-
Advancing siRNA Drug Discovery and Development with AI
Advancing siRNA Drug Discovery and Development with AI
-
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
-
Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia
Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia.
-
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
-
Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059
Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059
-
Viktig milstolpe nådd när Ribocure Clinic tar in sina första patienter
Viktig milstolpe nådd när Ribocure Clinic tar in sina första patienter
-
Ribocure Clinic marks milestone with their first patients enrolled
Ribocure Clinic marks milestone with their first patients enrolled
